Claritev Corporation
NYSE:CTEVMedical - Healthcare Information Services
+$0.42 today
- Market cap
- $380.77M
- Beta
- 0.77
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$17.16
Volume 0.31M
Average 0.14M
CTEV Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Claritev CorporationNYSE: CTEV
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables dips below year-ago levels
Q1 FY2026 accounts payables of $1.29M (cash outflow) fell 96.5% year over year, behind the +145.8% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 2.7% of revenue in FY2025, down 1.9 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -96.5% toward the trailing-twelve-month pace of +145.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (25.86M) USD
- Year-over-year change
- -161.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (25.86M) | -161.3% |
| FY2024 | 2024-12-31 | 42.22M | +656.8% |
| FY2023 | 2023-12-31 | 5.58M | -83.8% |
| FY2022 | 2022-12-31 | 34.35M | +345.3% |
| FY2021 | 2021-12-31 | 7.71M | — |
Accounts Payables vs competitors
How CTEV compares with its peers on the latest reported figures
- CTEV's LTM Mar 2026 accounts payables of $9.6M is the 5th largest of the 11 companies compared; the peer median is $5.41M.
- Its year-over-year change of +145.8% is the 5th highest of 11, against a peer median of +48.4%.
- Accounts payables amounts to 1.0% of revenue for CTEV, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $25.54M | +1844.4% | +15.5% | 1.6% | |
| LTM Mar 2026 | $22.2M | +85.3% | +14.8% | 3.8% | |
| LTM Mar 2026 | $11.08M | +237.4% | +37.4% | 5.0% | |
| LTM Jun 2026 | $9.69M | +1.8% | +70.4% | 508.8% | |
CTEVClaritev Corporation | LTM Mar 2026 | $9.6M | +145.8% | — | 1.0% |
| LTM Sep 2026 | $9.19M | +514.4% | — | 3.4% | |
| LTM Mar 2026 | $8.76M | -45.0% | -20.4% | 0.5% | |
| LTM Mar 2026 | $2.05M | +11.5% | -17.9% | 0.5% | |
| LTM Mar 2026 | $1.13M | +163.5% | — | — | |
| LTM Mar 2026 | $1.13M | -93.9% | — | 0.1% | |
| LTM Mar 2026 | $407.64K | -186.3% | — | 0.5% | |
| Peer median (excluding CTEV) | $5.41M | +48.4% | +15.2% | 1.6% | |
Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 102.08M | (572.91M) | (91.7M) | (1.65B) | (284.28M) |
| Depreciation & Amortization | 424.32M | 415.66M | 425.79M | 436.44M | 445.43M |
| Deferred Income Tax | (81.93M) | (114.38M) | (114.06M) | (198.01M) | (128.51M) |
| Stock-Based Compensation | 18.01M | 16.74M | 18.02M | 26.65M | 27.82M |
| Change in Working Capital | (46.68M) | 55.34M | (21.91M) | (13.67M) | (28.87M) |
| Accounts Receivables | (33.83M) | 21M | 4.4M | (13.2M) | (26.57M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.71M | 34.35M | 5.58M | 42.22M | (25.86M) |
| Other Working Capital | (12.85M) | 34.34M | (26.31M) | (42.69M) | 23.57M |
| Other Non-Cash Items | (93.04M) | 571.92M | (44.42M) | 1.5B | 85.73M |
| Operating Cash Flow | 404.69M | 372.36M | 171.72M | 107.62M | 117.32M |
| Capital Expenditures | (84.59M) | (89.74M) | (108.85M) | (118.12M) | (129.6M) |
| Acquisitions (Net) | (149.43M) | 0 | (140.94M) | 0 | 0 |
| Purchases of Investments | 0 | (15M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 289K | 0 | 0 | 16M |
| Other Investing Activities | 5.64M | 0 | 0 | 0 | (7.42M) |
| Investing Cash Flow | (228.38M) | (104.45M) | (249.79M) | (118.12M) | (121.02M) |
| Debt Repayment | (10.9M) | (13.28M) | (165.82M) | (28.07M) | 4.72M |
| Common Stock Issued | 0 | 0 | 508K | 0 | 1.74M |
| Common Stock Repurchased | (103.79M) | (100M) | (15.22M) | (10.37M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.79M) | (2.46M) | (465K) | (2.88M) | (4.1M) |
| Financing Cash Flow | (114.68M) | (115.74M) | (180.99M) | (41.32M) | 2.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 61.62M | 152.18M | (259.07M) | (51.82M) | (1.33M) |
| Free Cash Flow | 320.1M | 282.63M | 62.87M | (10.51M) | (12.28M) |
Claritev Corporation
NYSE:CTEV
Intrinsic Alpha fair value
Locked
Current Price
$22.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.